| (Values in U.S. Thousands) | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 |
| Sales | 33,750 | 9,120 | 17,850 | 15,660 | 10,110 |
| Sales Growth | +270.07% | -48.91% | +13.98% | +54.90% | -44.51% |
| Net Income | 18,320 | -5,500 | 2,360 | 160 | -3,620 |
| Net Income Growth | +433.09% | -333.05% | +1,375.00% | +104.42% | -155.78% |
Protalix Biotherapeutics (PLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Protalix BioTherapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of recombinant therapeutic proteins. The company's product pipeline includes ProCellEx(R). Protalix BioTherapeutics Inc. is based in CARMIEL, Israel.
Fiscal Year End Date: 12/31